Anton Lindberg1, Shuiyu Lu2, Sangram Nag3, Magnus Schou4, Jeih-San Liow2, Sami S Zoghbi2, Michael P Frankland2, Robert L Gladding2, Cheryl L Morse2, Akihiro Takano3, Nahid Amini3, Charles S Elmore5, Yong Sok Lee6, Robert B Innis2, Christer Halldin3, Victor W Pike2. 1. Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176 Stockholm, Sweden; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1003, USA. Electronic address: anton.lindberg@ki.se. 2. Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1003, USA. 3. Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176 Stockholm, Sweden. 4. Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176 Stockholm, Sweden; PET Science Centre, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, SE-17176 Stockholm, Sweden. 5. Isotope Chemistry, Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, SE-43250 Göteborg, Sweden. 6. Center for Molecular Modeling, Center for Information Technology, National Institutes of Health, Bethesda, MD 20892-5624, USA.
Abstract
INTRODUCTION: The serotonin 1B receptor subtype is of interest in the pathophysiology and treatment of depression, anxiety, and migraine. Over recent years 5-HT1B receptor binding in human brain has been examined with PET using radioligands that are partial but not full agonists. To explore how the intrinsic activity of a PET radioligand may affect imaging performance, two high-affinity full 5-HT1B receptor agonists (AZ11136118, 4; and AZ11895987, 5) were selected from a large compound library and radiolabeled for PET examination in non-human primates. METHODS: [11C]4 was obtained through Pd(0)-mediated insertion of [11C]carbon monoxide between prepared iodoarene and homochiral amine precursors. [11C]5 was obtained through N-11C-methylation of N-desmethyl precursor 6 with [11C]methyl triflate. [11C]4 and [11C]5 were studied with PET in rhesus or cynomolgus monkey. [11C]4 was studied with PET in mice and rats to measure brain uptake and specific binding. Ex-vivo experiments in rats were performed to identify whether there were radiometabolites in brain. Physiochemical parameters for [11C]4 (pKa, logD and conformational energetics) were evaluated. RESULTS: Both [11C]4 and [11C]5 were successfully produced in high radiochemical purity and in adequate amounts for PET experiments. After intravenous injection of [11C]4, brain radioactivity peaked at a low level (0.2 SUV). Pretreatment with tariquidar, an inhibitor of the brain P-gp efflux transporter, increased brain exposure four-fold whereas pretreatment with a high pharmacological dose of the 5-HT1B antagonist, AR-A000002, had no effect on the binding. Ex-vivo experiments in rats showed no radiometabolites entering brain. [11C]5 also failed to enter monkey brain under baseline conditions. CONCLUSIONS: [11C]4 and [11C]5 show too low brain uptake and specific binding to be useful PET radioligands. Low brain uptake is partly ascribed to efflux transporter action as well as unfavorable conformations.
<span class="abstract_title">INTRODUCTION: The <span class="Chemical">serotonin 1B receptor subtype is of interest in the pathophysiology and treatment of depression, anxiety, and migraine. Over recent years 5-HT1B receptor binding in human brain has been examined with PET using radioligands that are partial but not full agonists. To explore how the intrinsic activity of a PET radioligand may affect imaging performance, two high-affinity full 5-HT1B receptor agonists (AZ11136118, 4; and AZ11895987, 5) were selected from a large compound library and radiolabeled for PET examination in non-human primates. METHODS: [11C]4 was obtained through Pd(0)-mediated insertion of [11C]carbon monoxide between prepared iodoarene and homochiral amine precursors. [11C]5 was obtained through N-11C-methylation of N-desmethyl precursor 6 with [11C]methyl triflate. [11C]4 and [11C]5 were studied with PET in rhesus or cynomolgus monkey. [11C]4 was studied with PET in mice and rats to measure brain uptake and specific binding. Ex-vivo experiments in rats were performed to identify whether there were radiometabolites in brain. Physiochemical parameters for [11C]4 (pKa, logD and conformational energetics) were evaluated. RESULTS: Both [11C]4 and [11C]5 were successfully produced in high radiochemical purity and in adequate amounts for PET experiments. After intravenous injection of [11C]4, brain radioactivity peaked at a low level (0.2 SUV). Pretreatment with tariquidar, an inhibitor of the brain P-gp efflux transporter, increased brain exposure four-fold whereas pretreatment with a high pharmacological dose of the 5-HT1B antagonist, AR-A000002, had no effect on the binding. Ex-vivo experiments in rats showed no radiometabolites entering brain. [11C]5 also failed to enter monkey brain under baseline conditions. CONCLUSIONS: [11C]4 and [11C]5 show too low brain uptake and specific binding to be useful PET radioligands. Low brain uptake is partly ascribed to efflux transporter action as well as unfavorable conformations.
Authors: Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-13 Impact factor: 9.236
Authors: P Karlsson; L Farde; C Halldin; C G Swahn; G Sedvall; C Foged; K T Hansen; B Skrumsager Journal: Psychopharmacology (Berl) Date: 1993 Impact factor: 4.530
Authors: M Edward Pierson; Jan Andersson; Svante Nyberg; Dennis J McCarthy; Sjoerd J Finnema; Katarina Varnäs; Akihiro Takano; Per Karlsson; Balázs Gulyás; Amy M Medd; Chi-Ming Lee; Mark E Powell; J Richard Heys; William Potts; Nicholas Seneca; Ladislav Mrzljak; Lars Farde; Christer Halldin Journal: Neuroimage Date: 2008-03-14 Impact factor: 6.556
Authors: Anton Lindberg; Ryosuke Arakawa; Tsuyoshi Nogami; Sangram Nag; Magnus Schou; Charles S Elmore; Lars Farde; Victor W Pike; Christer Halldin Journal: EJNMMI Res Date: 2019-11-21 Impact factor: 3.138